Pharmacy

Your Article Summary

See Latest Articles

Abbott Adds Hepatitis B Test to its Broad Menu of Immunoassays on the ARCHITECT i 2000 and i 2000SR
Abbott, 05/15/09

Abbott announced that it has received premarket approval from the U.S. Food and Drug Administration for ARCHITECT CORE, an automated hepatitis B test for use on its ARCHITECT i 2000 and i 2000SR immunoassay testing instruments. ARCHITECT CORE is a chemiluminescent microparticle immunoassay for the qualitative detection of IgG and IgM antibodies to hepatitis B core antigen in human adult and pediatric serum and plasma and neonatal serum. It is intended as an aid in diagnosis of acute, chronic or resolved hepatitis B virus infection in conjunction with other laboratory results and clinical information.

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09

Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09

 See all of Drug Approvals

Today in Drug/Product Alerts...keeping you current

Receive free subspecialty "5-minute updates" via email

Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09

 See all of Drug/Product Alerts